Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal

Novartis is forging ahead with a prospective stem cell biotech buyout, agreeing to pay $35 million to grab a sizable equity stake in Gamida Cell while executing a short term option deal that will allow the pharma giant the right to gobble up the company for another $600 million split up between a $165 million upfront payout with the rest up for grabs in development and sales milestones.

Novartis circles back with new terms for a stem cell biotech buyout--report

Novartis' on-again, off-again deal to buy out Israeli stem cell therapy developer Gamida Cell is reportedly back on again--though the pharma giant has apparently renegotiated the old $600 million pact to include a smaller upfront buy-in and one of its favored option agreements.

The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A

Why do cancer drugs cost so much? We all know the stock answer--because companies need to recoup their development costs. Whether we believe it is something else, as Peter Bach of the Center for Health Policy and Outcomes writes in Forbes.

New era about to dawn: Novartis, and now Celltrion, present biosimilars to the FDA

Biosimilars promise huge potential, with estimates for this decade running from $35 billion to $200 billion and growing exponentially from there. And of course the U.S., being the world's largest pharma market, presents the greatest potential, once someone breaks in and acceptance can be judged.

Novartis can't convince judge to free it from kickbacks case

Novartis has failed again to convince a federal judge to boot a Department of Justice kickbacks case against it that claims the Swiss drugmaker showered pharmacies with discounts and rebates to boost sales of two drugs.

The top 15 late-stage blockbusters in the pipeline

In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd. Read the full report >>

How big is Novartis' LCZ696 heart drug? Experts bet on a key number

In the pharma business, you're only as good as your next big blockbuster. And in Novartis' case, the next big cardio blockbuster--LCZ696--looks very good, indeed.

Novartis' U.S. Diovan plant gets 'For Sale' sign

When Novartis put a closure target on its plant in Suffern, NY, it indicated that it might go as far as to strip out the equipment, raze the buildings and sell empty land. But the 160-acre campus is now officially on the block and being brokered as a great buy for the right drug manufacturer.

U.K. and Novartis begin price negotiations on Bexsero

Let the negotiations begin. After pushing back on the price of Novartis' meningitis B vaccine, Bexsero, the U.K. is coming to the table with the Swiss drugmaker to see if it can haggle down the cost to its health system.

Novartis apologizes for lax business practices in Japan as side-effects scandal widens

Facing its second scandal in as many months, Novartis' Japanese unit has issued an apology for failing to disclose side effects of its drugs Tasigna and Gleevec, which are used to treat leukemia.